I CAN tell you simply, the patient count makes a d
Post# of 72440
The four-arm multi-center Phase 2 trial, three arms with different dosing regimens of Prurisol and one arm placebo, is designed to assess the efficacy and safety of Prurisol given orally compared to placebo in a randomized, double-blind setting in patients with mild to moderate chronic plaque psoriasis. The trial was expected to enroll 100 subjects and actually enrolled 115 subjects. The primary efficacy endpoint will be the percentage of subjects with greater than or equal to a 2-point improvement in Investigator’s Global Assessment (IGA) rating as defined by visual inspections of patient lesions. The final study visit for the last subject is expected early in April 2016, with top-line data anticipated approximately four weeks later. - See more at: http://cellceutix.com/cellceutix-phase-2-tria...N3ChA.dpuf
Quote:
Posted On: 02/03/2016 7:44:40 AM
Posted By: takingabath
Re: BooDog #18209
If there is no significance then there would be no need to point out the extra 15 patients...imo...
and for whatever reason the count was exceeded I'll stick to my theory that using multiple clinics can simply have this effect. Consider the Dr. admitting/prescribing and having a clue.